Special attention has been paid to point out how NLRP3 inflammasome influences the dynamic interplay between microbiota, intestinal epithelium, and innate immune system, as well as how the pharmacological modulation of this enzymatic complex could represent a suitable strategy in the management of inflammatory bowel diseases (IBDs). The gene discussed is NLRP3; the disease is inflammatory bowel disease.